Pulmonary surfactant and nanocarriers: Toxicity versus combined nanomedical applications

摘要

Abstract Pulmonary surfactant is a membrane-based lipid-protein system essential for the process of breathing, which coats and stabilizes the whole respiratory surface and possesses exceptional biophysical properties. It constitutes the first barrier against the entry of pathogens and harmful particles in the alveolar region, extended through the lungs, but on the other hand, it can offer novel possibilities as a shuttle for the delivery of drugs and nanocarriers. The advances in nanotechnology are opening the doors to new diagnostic and therapeutic avenues, which are not accessible by means of the current approaches. In this context, the pulmonary route is called to become a powerful way of entry for innovative treatments based on nanotechnology. In this review, the anatomy of the respiratory system and its properties for drug entry are first revisited, as well as some current strategies that use the respiratory route for both local and peripheral action. Then, a brief overview is presented on what pulmonary surfactant is, how it works and why it could be used as a drug delivery vehicle. Finally, the review is closed with a description of the development of nanocarriers in the lung context and their interaction with endogenous and clinical pulmonary surfactants. This article is part of a Special Issue entitled: Membrane Lipid Therapy: Drugs Targeting Biomembranes edited by Pablo V. Escribá. Highlights ? The pulmonary route can be a powerful way of entry for innovative treatments based on nanotechnology. ? Pulmonary surfactant is the first barrier against the entry of pathogens and harmful particles in alveoli. ? Pulmonary surfactant can offer novel possibilities as a shuttle for delivery of drugs and nanocarriers. ? Nanocarrier/surfactant interaction has to be analyzed to optimize novel nanomedicine approaches. ]]>